LTGO
NASDAQLatigo Biotherapeutics Inc.
Latigo Biotherapeutics Inc. (LTGO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for LTGO, including 2 SEC filings, 1 press release or news item and 1 leadership change. The most recent was published Nov 6, 2026.
LTGO rankings
Price$12.52-2.33 (-15.69%)
02:30 PM08:45 PM
News · 26 weeks6+100%
2026-05-102026-11-01
Mix690d
- SEC Filings2(33%)
- Other1(17%)
- Leadership1(17%)
- Earnings1(17%)
- 13D/G1(17%)
Activity · 52 weeks63 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
6 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Latigo Biotherapeutics Inc.SCHEDULE 13G/A - Latigo Biotherapeutics, Inc. (0002056611) (Subject)
- SECSEC Form 10-Q filed by Latigo Biotherapeutics Inc.10-Q - Latigo Biotherapeutics, Inc. (0002056611) (Filer)
- SECLatigo Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Latigo Biotherapeutics, Inc. (0002056611) (Filer)
- PRLatigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsPhase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans to add oxycodone/acetaminophen (commonly known as Percocet) as opioid comparator arm to the Phase 3 bunionectomy trial Phase 2 trial of LTG-321 for the treatment of chronic pain is currently ongoing; Expect to report topline results in the second half of 2027 Cash and cash equivalents of $401 million expected to fund operations into 2029 THOUSAND OAKS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (NASDAQ:LTGO), a clinical-stage biopharmaceutical company committed to developing innovativ
- PRLatigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of GrowthTodd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of the Company’s pipeline of non-opioid pain treatment programs Nima Farzan will remain as a strategic advisor through 2027 THOUSAND OAKS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (NASDAQ:LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the appointment of Todd N. Smith as president and chief executive officer (CEO), effective immediately. Mr. Smith, who has served as
- PRLatigo Biotherapeutics to Participate in Upcoming Investor Conferences in NovemberTHOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (NASDAQ:LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced that management will participate in the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference – Boston, MAFireside chat on Tuesday, November 10, 2026, at 8:30 a.m. ET Jefferies Global Healthcare Conference – London, UKFireside chat on Monday, November 16, 2026, at 3:30 p.m. GMT The Latigo management team will also be available to participate in 1x1 meetings with investors who are registered to attend the conferences. A replay of the we
LTGO FAQ
7 questionsWhat does Latigo Biotherapeutics Inc. do?
Latigo Biotherapeutics is a private clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo is supported by leading investors, including Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital. Latigo's lead program is LTG-001, an oral, selective Nav1.8 inhibitor in development to treat acute pain.What is the latest news on LTGO?
In the last 30 days Quantisnow tracked 6 wire items for LTGO: 2 SEC filings, 1 press release or news item, 1 leadership change and 1 earnings update. The most recent was published on November 6, 2026.Where does LTGO stock trade?
Latigo Biotherapeutics Inc. (LTGO) is listed on NASDAQ.What sector and industry is LTGO in?
Latigo Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Latigo Biotherapeutics Inc. go public?
Latigo Biotherapeutics Inc. (LTGO) completed its IPO in 2026.What companies are similar to LTGO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LTGO side-by-side with any of them on Quantisnow.How can I track LTGO on Quantisnow?
Quantisnow aggregates Latigo Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LTGO to receive live email and push alerts on every new disclosure.